UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q/A
Amendment No.1
(Mark One)
|
x
|
QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
|
For the quarterly period ended June 30, 2011
|
o
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
|
For the transition period from ____________ to ____________
Commission File Number 001-34471
CHINA PHARMA HOLDINGS, INC.
(Exact name of registrant as specified in its charter)
|
Delaware
|
73-1564807
|
|
(State or other jurisdiction of
|
(IRS Employer
|
|
incorporation or organization)
|
Identification No.)
|
Second Floor, No. 17, Jinpan Road
Haikou, Hainan Province, China 570216
(Address of principal executive offices) (Zip Code)
+86 898-6681-1730 (China)
(Issuer's telephone number, including area code)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes o No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check One):
|
Large accelerated filer o
|
Accelerated filer o
|
|
Non-accelerated filer o
(Do not check if a smaller reporting company)
|
Smaller reporting company x
|
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x
APPLICABLE ONLY TO CORPORATE ISSUERS:
Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date: 43,529,557 shares of Common Stock, $.001 par value, were outstanding as of August 9, 2011.
Explanatory Note
The purpose of this Amendment No. 1 on Form 10-Q/A to China Pharma Holdings, Inc.’s Quarterly Report on Form 10-Q for the period ended June 30, 2011, filed with the Securities and Exchange Commission on August 10, 2011 (“the Form 10-Q”), is solely to furnish Exhibit 101 to the Form 10-Q in accordance with Rule 405 of Regulation S-T. Exhibit 101 consists of the following materials from China Pharma Holdings, Inc.’s Form 10-Q, formatted in XBRL (eXtensible Business Reporting Language):
|
101.INS
|
XBRL Instance Document
|
|
101.SCH
|
XBRL Taxonomy Extension Schema Document
|
|
101.CAL
|
XBRL Taxonomy Extension Calculation Linkbase Document
|
|
101.DEF
|
XBRL Taxonomy Extension Definition Linkbase Document
|
|
101.LAB
|
XBRL Taxonomy Extension Label Linkbase Document
|
|
101.PRE
|
XBRL Taxonomy Extension Presentation Linkbase Document
|
No other changes have been made to the Form 10-Q and this Form 10-Q/A does not modify or update any other disclosures made in the Form 10-Q.
Pursuant to Rule 406T of Regulation S-T, the interactive data files on Exhibit 101 hereto are deemed not filed as part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, are deemed not filed for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, and otherwise are not subject to liability under those sections.
PART II. OTHER INFORMATION
Item 6. Exhibits
The exhibits set forth on the accompanying Exhibit Index have been filed as part of this Form 10-Q/A.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| |
CHINA PHARMA HOLDINGS, INC.
|
|
| |
|
|
|
|
Date: September 6, 2011
|
By:
|
/ s/ Zhilin Li
|
|
| |
|
Name: Zhilin Li
|
|
| |
|
Title: President and Chief Executive Officer
|
|
| |
|
(principal executive officer)
|
|
| |
|
|
|
| |
|
|
|
|
Date: September 6, 2011
|
By:
|
/s/ Frank Waung
|
|
| |
|
Name: Frank Waung
|
|
| |
|
Title: Chief Financial Officer
|
|
| |
|
(principal financial officer and principal
|
|
| |
|
accounting officer)
|
|
EXHIBIT INDEX
No. Description
3.1* – Amended and Restated Bylaws
10.1 – Employment Agreement with Mr. Frank Waung, incorporated by reference to Exhibit 10.3 to the Current Report on Form 8-K filed with the SEC on June 1, 2011.
31.1* – Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2* – Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1* – Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2* – Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
|
101.INS**
|
XBRL Instance Document
|
| |
|
|
101.SCH**
|
XBRL Taxonomy Extension Schema Document
|
| |
|
|
101.CAL**
|
XBRL Taxonomy Extension Calculation Linkbase Document
|
| |
|
|
101.DEF**
|
XBRL Taxonomy Extension Definition Linkbase Document
|
| |
|
|
101.LAB**
|
XBRL Taxonomy Extension Label Linkbase Document
|
| |
|
|
101.PRE**
|
XBRL Taxonomy Extension Presentation Linkbase Document
|
* Exhibits filed with China Pharma Holdings, Inc.’s Quarterly Report on Form 10-Q as filed with Securities and Exchange Commission on August 10, 2011.
** Filed herewith.